肠系膜上动脉支架内再狭窄的自然病史
单中心回顾性研究纳入2003至2020年186例因慢性肠系膜缺血行肠系膜上动脉支架置入的患者,分析支架内再狭窄程度与症状复发的关系。峰值收缩速度不能预测症状复发(AUC=0.49;95%CI 0.40-0.57)。无症状与有症状再狭窄组在支架类型、再狭窄时间及腹腔动脉干预上无差异,术前抗血小板药物使用在无症状组更常见。
要点
- 峰值收缩速度不能预测慢性肠系膜缺血患者支架内再狭窄后的症状复发。
- 无症状再狭窄组术前抗血小板药物使用比例高于有症状组(86% vs 65%;P=0.015)。
- 无症状与有症状再狭窄组在支架类型、再狭窄时间及腹腔动脉干预上无差异。
核心结论
- 肠系膜上动脉支架内再狭窄的自然病史此前未被描述;峰值收缩速度升高对症状复发的预测能力差。
- 无症状与有症状的支架内再狭窄患者在支架类型、再狭窄时间或腹腔动脉受累上无差异。
- 术前和术后使用抗血小板药物似乎对症状复发具有保护作用。
- 作者认为研究结果强调需要长期监测,整合临床评估和必要时多模态影像。
研究设计与样本
- 单中心回顾性研究纳入2003至2020年因慢性肠系膜缺血行肠系膜上动脉支架置入的患者。
- 随访分析包括症状复发、双功能超声、计算机断层扫描血管造影和血管造影。
- 采用受试者工作特征曲线分析评估峰值收缩速度是否预测症状复发。
- 对支架内再狭窄患者进行亚组分析(无症状和有症状),再狭窄定义为双功能超声峰值收缩速度≥350。
主要发现
- 研究纳入186例患者,受试者工作特征曲线分析基于503次术后随访。
- 峰值收缩速度不是症状复发的预测因子,曲线下面积=0.49(95%置信区间0.40-0.57)。
- 计算机断层扫描血管造影与血管造影的一致性(曲线下面积0.769;95%置信区间0.688-0.849)高于计算机断层扫描血管造影与双功能超声的一致性(曲线下面积0.650;95%置信区间0.589-0.711)。
- 支架内再狭窄亚组分析纳入99例患者(无症状组67例;有症状组32例)。
- 无症状组与有症状组再狭窄中位时间(月)无统计学差异:4.5(无症状组) vs 7.6(有症状组)。
关键数值与推荐
- 再狭窄由双功能超声定义为峰值收缩速度≥350。
- 峰值收缩速度预测症状复发的曲线下面积=0.49(95%置信区间0.40-0.57)。
- 计算机断层扫描血管造影与血管造影的一致性曲线下面积=0.769(95%置信区间0.688-0.849)。
- 计算机断层扫描血管造影与双功能超声的一致性曲线下面积=0.650(95%置信区间0.589-0.711)。
临床怎么用
- 作者认为研究结果强调需要长期监测,整合临床评估和必要时多模态影像。
- 作者指出术前和术后使用抗血小板药物似乎对症状复发具有保护作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Superior mesenteric artery (SMA) stenting is the preferred approach for patients with symptomatic SMA-associated chronic mesenteric ischemia (CMI). The durability of this modality is impacted by in-stent restenosis (ISR). Duplex ultrasound (DUS) and computed tomographic angiography (CTA)-measured ISR may be weakly correlated and not uniformly associated with recurrence of presenting symptoms. This study aims to analyze the association between the degree of ISR for patients with CMI and to develop a predictive model for symptom recurrence. METHODS: Single center, retrospective study included all patients with CMI with SMA stents from the period of 2003 to 2020. Follow-up period analysis included patients' symptoms recurrence, DUS, CTA, and angiography. A receiver operating characteristic (ROC) analysis was used to evaluate whether peak systolic velocity (PSV) was predictive of symptom recurrence. A subgroup analysis of patients (asymptomatic and symptomatic) with SMA ISR was identified; restenosis defined by DUS with peak systolic velocity (PSV) ≥350. RESULTS: The study included 186 patients with the ROC analysis obtained from 503 postoperative visits. PSV was not a predictor of symptoms return with area under the curve (AUC) = 0.49 (95% confidence interval [CI], 0.40-0.57). Agreement analysis between imaging modalities showed higher agreement between CTA and angiogram (AUC, 0.769; 95% CI, 0.688-0.849) vs CTA and DUS (AUC, 0.650; 95% CI, 0.589-0.711). The subgroup analysis of patients with ISR included 99 patients (asymptomatic n = 67; symptomatic n = 32). There was no statistical difference between median time (months) to ISR between both groups: 4.5 (asymptomatic group) and 7.6 (symptomatic group). The use of preoperative antiplatelet (86% vs 65%; P = .015) and P2Y12 receptor blockers (36% vs 13%; P = .016) was more prevalent in the asymptomatic group. There was no difference between the type or number of stents placed, stent diameter, or concomitant celiac artery intervention between both groups. CONCLUSIONS: The natural history of SMA and multimodality defined ISR in CMI has not previously been described. Elevated PSV was a poor predictor of symptoms recurrence. Both asymptomatic and symptomatic patients with ISR did not differ in type of stent placed, time to ISR, or involvement of celiac artery. Antiplatelet use pre- and postoperatively appears protective against symptoms recurrence. Our findings underscore the need for long-term surveillance integrating clinical evaluation and multimodality imaging when indicated.
引用
- Sorour AA, Dehaini H, Alnahhal KI, et al. Natural history of superior mesenteric artery in-stent restenosis. J Vasc Surg. 2023. PMID: 38128845. doi:10.1016/j.jvs.2023.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。